Answers are grounded in this paper and cite their sources.
To evaluate the effects of the evidence-based Tailored Activity Program (TAP) on neuropsychiatric symptoms (NPS) and cognitive function among people living with dementia (PLWD), as well as the well-being of their caregivers in China. A single-blind, two-arm randomised waitlist-controlled trial was conducted. A total of 64 PLWD-caregiver dyads were enrolled from January 2022 to December 2023 and randomly assigned to either the TAP intervention group (n = 32) or waitlist control group (n = 32). The TAP intervention group received two consecutive 12-week TAP cycles (Cycle 1: weeks 1–12; Cycle 2: weeks 13–24). Each cycle adopted the three-stage assessment-implementation-generalisation framework, consisting of eight visits (five home visits and three telephone follow-ups). All visits were delivered within each 12-week intervention period rather than serving merely as maintenance follow-ups. The control group received standard community home-visiting services in the first 12 weeks, followed by the identical TAP intervention in the subsequent 12 weeks. Data were collected at baseline (T0), week 12 (T1), and week 24 (T2). Primary outcomes included neuropsychiatric symptoms, cognitive function, and quality of life of PLWD. Secondary outcomes comprised caregiver burden and depressive symptoms. In this waitlist-controlled trial, linear mixed-effects models revealed significant time-by-group interactions for NPI, QOL-AD, ZBI and CES-D. At T1 and T2, large-magnitude between-group differences favoured the intervention: NPI (T1: -15.22, 95% CI -22.87 to -7.56, Cohen’s d = 1.059; T2: -16.46, 95% CI -24.11 to -8.80, Cohen’s d = 1.250); QOL-AD (T1: 3.86, 95% CI 2.02 to 5.70, Cohen’s d = 1.131; T2: 3.25, 95% CI 1.41 to 5.09, Cohen’s d = 0.901); ZBI (T1: -10.61, 95% CI -15.92 to -5.30, Cohen’s d = 0.906; T2: -11.49, 95% CI -16.80 to -6.18, Cohen’s d = 1.041); CES-D (T1: -6.37, 95% CI -9.82 to -2.92, Cohen’s d = 0.932; T2: -6.06, 95% CI -9.50 to -2.61, Cohen’s d = 1.090). These findings suggest potential clinical benefits in reducing neuropsychiatric symptoms, improving quality of life for PLWD, and lowering caregiver burden and depressive symptoms. For MMSE, no significant time, group or interaction effects were detected; borderline between-group differences (T1: 2.80, 95% CI -0.11 to 5.71; T2: 2.84, 95% CI -0.07 to 5.75) with small-to-moderate effect sizes provided insufficient evidence of cognitive improvement. TAP was associated with large improvements in neuropsychiatric symptoms and quality of life for PLWD, as well as reductions in caregiver burden and depressive symptoms. No consistent evidence of cognitive benefits was identified. Owing to limitations of the waitlist crossover design, 24-week follow-up findings are exploratory. Larger studies are required to examine cognitive outcomes and different intervention durations of TAP. ChiCTR2500114438. Registered on 11 December 2025 at the Chinese Clinical Trial Registry (ChiCTR, http://www.chictr.org.cn).
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: